Select your Market
-
- Algeria
- Angola
- Benin
- Botswana
- Burkina Faso
- Burundi
- Cameroon
- Cape Verde
- Central African Republic
- Chad
- Comoros
- Congo
- Congo Democratic Republic
- Djibouti
- Egypt
- Equatorial Guinea
- Eritrea
- Ethiopia
- Gabon
- Gambia
- Ghana
- Guinea
- Guinea-Bissau
- Ivory Coast
- Kenya
- Lesotho
- Liberia
- Libya
- Madagascar
- Malawi
- Mauritania
- Mauritius
- Morocco
- Mozambique
- Namibia
- Niger
- Nigeria
- Reunion Islands
- Rwanda
- Saint Helena
- São Tomé and Príncipe
- Senegal
- Seychelles
- Sierra Leone
- Somalia
- South Africa
- Sudan
- Swaziland
- Tanzania
- Togo
- Tunisia
- Uganda
- Zambia
- Zimbabwe
-
- Albania
- Austria
- Baltic Region
- Belarus
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Netherlands
- North Macedonia
- Norway
- Poland
- Portugal
- Romania
- Russian Federation
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Türkiye
- Ukraine
- United Kingdom
Vibrant science across the globe
Patients are at the center of all our research and development efforts. We are committed to innovation in science that will ultimately make a meaningful difference in people’s lives all over the world. Ever since Merck KGaA, Darmstadt, Germany, was founded 350 years ago, we have gained unmatched experience in the discovery, development and manufacturing of medicines.
On top of leveraging our experience and expertise, we also believe that a healthier future deserves a sizable investment. In 2018 our Healthcare business devoted roughly 20% of total sales to R&D activities aimed at discovering and developing new therapies. All of these are integrated in a global organization with six strategic locations and highly connected hubs: Darmstadt, Boston, Beijing, Tokyo, Bangalore, and Yavne.
Our pipeline
View our robust R&D pipeline across Immunology, Oncology, and Immuno-Oncology to see what we’re currently working on.
View our R&D pipelineLatest R&D News
View All News-
Press Releases
Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening ...
We enter into a definitive agreement to acquire biotechnology company Silence Therapeutics, focused on siRNA-therapies in areas of high unmet need.
2026/10/19
-
Press Releases
Collaboration with Versant to Launch Saturnus Bio
Merck KGaA, Darmstadt, Germany Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
2026/06/23
-
Press Releases
2026 Future Insight Prize Goes to Spear’s Vasilis Ntziachristos
The € 300,000 research grant award recognizes Ntziachristos’ pioneering work in enabling non-invasive and continuous monitoring of human biology.
2026/06/23
Partner with us
Productive partnerships
Partner with our R&D experts to unlock your project’s potential. We believe in mutually beneficial alliances built on transparency and commitment to ambitious, well-defined goals. These can be many and varied. For example, to help bring innovations to market, or to better market commercial products. Whatever your project, we are excited to hear your proposal!
Read more
Grants & Awards
Innovators wanted! We highly value creativity, initiative and innovation. So, it’s very important to us that we recognize scientists, students and entrepreneurs who exhibit these qualities in outstanding work.
Read moreUS/NPR/0517/0230(1)a(1)a